•Today, I’d like to present to you our next-generation endoscope system, EVIS X1, andits global market development strategies.

•The global key message for this product is “Let’s Be Clear - Elevating the Standard ofEndoscopy.”•I’d also like to introduce various new technologies that embody this message.

•First, let’s look at the overall business structure of Olympus.

•As you can see, approximately 80% of our revenue are from the medical field, which isOlympus’ largest core business.

•We provide a wide variety of medical products that can be broadly divided into twosegments: the Endoscopic Solutions Division and the Therapeutic Solutions Division.
(Medical field: 641.8 billion yen / Endoscopic Solutions Division: 425.7 billion yen /Therapeutic Solutions Division: 216.1 billion yen)•Endoscopic Solutions Division consists of gastrointestinal endoscopes, surgicalendoscopes, and medical services. Revenue of gastrointestinal endoscopes accountfor approximately 60% of total revenue, surgical endoscopes nearly 15%, and medicalservices nearly 30%.

•EVIS X1, which I will introduce today, is a key product representing the gastrointestinalendoscope area. It is positioned as the most important strategic product for Olympus’overall business performance.

•Take a look at these pie charts.

•They show the global market size of gastrointestinal endoscopes used for earlydiagnosis, and of surgical endoscopes and therapeutic devices used for minimallyinvasive therapy.

•As shown on the upper left, Olympus has over 70% of the global market share forgastrointestinal endoscopes.

•The new EVIS X1 is the core product in our gastrointestinal endoscope lineup.

•By competing and growing in this market, we aim to become a leading global playerin the medical area.

•At our corporate strategy briefing (held in November 2019), we explained that part ofour key strategy is strengthening our position in the gastrointestinal endoscopebusiness. We believe that EVIS X1 will contribute significantly to this initiative.

•At our corporate strategy briefing (held in November 2019), we explained that part ofour key strategy is strengthening our position in the gastrointestinal endoscopebusiness. We believe that the EVIS X1 will contribute significantly to this initiative.

•The values that Olympus’ medical business provide can be broadly divided into twocategories.

•One is early diagnosis, in which a person’s body is examined internally with agastrointestinal endoscope to check for diseases, as shown on the left side of the slide,•and the other is minimally invasive therapy, which is endoscopic therapy and surgerythat place minimal burden on patients shown on the right side.

•This EVIS X1 is backed up with new technologies to support the detection,characterization, staging and treatment steps of gastrointestinal diseases such ascancer. My colleague Kura will cover the details of the technology later.

•So far, I have covered our medical business.

•I’d like to return to our new endoscope system, EVIS X1.

•Launch of this product started in Europe and some parts of Asia on April 23, and inJapan on July 3.

•This endoscope system is a high-end model, and has undergone a model change fromthe previous models, the EVIS LUCERA ELITE and the EVIS EXERA III, after abouteight years.

•Although the EVIS X1 is Olympus’ first new product in the endoscope area, our corebusiness, in about eight years, the announcement came at a time when COVID-19continues to pose a threat to the world.

•Here, I would like to express our deepest condolences to those who have lost theirlives to COVID-19 and extend our deepest sympathy to those who have been affected.

•This pandemic is an unprecedented crisis, but it is also an opportunity for us to reaffirmthe importance of our responsibility as a global medtech company to reliably provideproducts and services to healthcare professionals on the front lines of the fight againstinfectious disease.

•The Olympus Group has already established a global task force to gather informationfrom around the world, support healthcare professionals, and take all necessarymeasures to contribute to patient health and safety.